Cardiac Monitor Implant Detects A-Fib in More Stroke Patients
Rate of incident AF over 12 months higher with implant versus usual care with external cardiac monitoring in patients with ischemic stroke
Stroke
Cause of First Stroke Guides Prevention of Second Stroke
Recommendations include diagnostic workup to define stroke etiology to reduce risk for recurrent stroke
Kidney Impairment Influences Safety, Efficacy of Anticoagulants for AFib
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
FDA Clears Novel Device for Upper Extremity Rehabilitation After Stroke
The device is available only with a prescription and may be used as part of rehabilitation therapy.
Brilinta Approved to Reduce Risk of Recurrent Stroke in High-Risk Patients
The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events.
Ticagrelor Under Review for Reduction of Subsequent Stroke in High-Risk Patients
The FDA has granted Priority Review of the supplemental New Drug Application for Brilinta (ticagrelor; AstraZeneca), for use in combination with aspirin, to reduce the rate of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.
Brilinta Approved to Reduce Risk of First MI, Stroke in High-Risk CAD Patients
The Food and Drug Administration has approved Brilinta (ticagrelor; AstraZeneca) to reduce the risk of a first myocardial infarction (MI) or stroke in high-risk patients with coronary artery disease (CAD).
Acute Neurologic Deficit Linked to Salicylate Toxicity
Due to her neurologic presentation, age, and past medical history, stroke was initially considered.
Alteplase Seems Beneficial at 4.5 to 9.0 Hours After Stroke
Trial terminated because of loss of equipoise after publication of positive results from previous trial
Linagliptin Non-Inferior to Glimepiride in Long-Term Cardiovascular Outcome Study
Boehringer Ingelheim and Lilly announced that the CAROLINA trial met its primary endpoint, demonstrating no increased cardiovascular (CV) risk with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.
